Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Integrated multi-omics identifies MCRS1 as a causal hub linking aging, metabolic syndrome, and breast cancer
Yiying Tao1, Xibing Ding1, Wei Xuan1
1Key Laboratory of Anesthesiology (Shanghai Jiao Tong University, Ministry of Education), Department of Anesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose:
Aging and metabolic syndrome (MetS) are intertwined risk factors for breast cancer (BC), but the core molecular nexus integrating these states is unknown. This study aimed to identify and validate a causal driver at this intersection.
Methods:
We integrated transcriptomic datasets from BC, MetS, and aging cohorts to identify common dysregulated genes. Machine learning algorithms prioritized a core diagnostic signature. We used Mendelian randomization to infer causality and characterized the lead candidate using single-cell RNA sequencing and comprehensive preclinical validation.
Results:
Our analysis identified a 25-gene core at the intersection of BC, MetS, and aging. Machine learning distilled this to five hub genes that formed a highly accurate diagnostic nomogram. Critically, Mendelian randomization established MCRS1 as the sole causal risk factor for BC among these candidates. Single-cell analysis revealed that Mcrs1 is predominantly expressed in proliferating cancer cells, where it drives a transcriptional program of enhanced cell cycle, senescence, and metabolic reprogramming. Accordingly, genetic knockdown of Mcrs1 profoundly suppressed BC cell proliferation and invasion in vitro, and in vivo experiments using an orthotopic BC model in C57BL/6 mice demonstrated significantly reduced tumor growth.
Conclusion:
This study identifies MCRS1 as a central molecular hub that causally links aging and MetS to BC pathogenesis. MCRS1 is a validated driver of tumor progression and a high-performance biomarker, representing a potential target for therapeutic development, particularly in BC patients with metabolic comorbidities.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Causality in Epidemiology
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
What is Metabolism?
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Criteria for Causality: Bradford Hill Criteria - II

